Update on Ankylosing Spondylitis: Current Concepts in Pathogenesis

• Published in: Current allergy and asthma reports Vol. 15; no. 1
• Main Author: Smith, Judith A.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.01.2015
• Subjects: Allergology; Autoimmunity (Tk Tarrant; Medicine; Medicine & Public Health; Section Editor; Topical Collection on Autoimmunity; Autoimmunity; Autoinflammatory disease; Pathogenesis; Interleukin-23; ERAP1; Ustekinumab; SKG model; Secukinumab; Spondyloarthritis; TNF-α; Mechanical stress; Genetics; Interleukin-17; Ankylosing spondylitis; Microbiome
• ISSN: 1529-7322; 1534-6315
• DOI: 10.1007/s11882-014-0489-6

Ankylosing spondylitis is an insidiously progressive and debilitating form of arthritis involving the axial skeleton. The long delay in diagnosis and insufficient response to currently available therapeutics both advocate for a greater understanding of disease pathogenesis. Genome-wide association studies of this highly genetic disease have implicated specific immune pathways, including the interleukin (IL)-17/IL-23 pathway, control of nuclear factor kappa B (NF-κB) activation, amino acid trimming for major histocompatibility complex (MHC) antigen presentation, and other genes controlling CD8 and CD4 T cell subsets. The relevance of these pathways has borne out in animal and human subject studies, in particular, the response to novel therapeutic agents. Genetics and the findings of autoantibodies in ankylosing spondylitis revisit the question of autoimmune vs. autoinflammatory etiology. As environmental partners to genetics, recent attention has focused on the roles of microbiota and biomechanical stress in initiating and perpetuating inflammation. Herein, we review these current developments in the investigation of ankylosing spondylitis pathogenesis.